Skip to content
Free previewYou are reading 1 of 36 lessons, in the same interface members use. Everything else unlocks with full access.Get full access · $150

1.1.1 - Regulatory, HTA and Payer Decisions

HEOR Evidence Planning / Decision Roles and Questions

Regulatory, HTA and payer decisions

Health economics and outcomes research (HEOR) supports several decisions that use overlapping evidence but answer different questions. Your first responsibility is to identify the decision, its owner and the conclusion the evidence can support.

What you will learn

  • Distinguish regulatory benefit-risk evaluation, comparative clinical assessment, economic evaluation, reimbursement and price negotiation. Mapping: HEOR decisions and evidence planning / Distinguish regulatory, HTA and payer decisions.
  • Assign appropriate contributions to developers, regulators, health technology assessment bodies, payers, clinicians, patients and evidence analysts. Mapping: HEOR decisions and evidence planning / Stakeholder roles.
  • Explain what an EU JCA establishes and what remains for national and payer decisions. Mapping: HEOR decisions and evidence planning / Relative clinical effects and uncertainty.
  • Recognize the limits of an educational completion certificate. Mapping: HEOR decisions and evidence planning / Credential distinctions.
Estimated time
20-25 minutes for the main lesson; allow additional time for all practice rationales.
Blueprint mapping
HEOR decisions and evidence planning → Distinguish regulatory, HTA and payer decisions → parent domain weight 10%; a separate topic weight is not supplied.
Current context
November 5, 2026. European Union joint clinical assessments (EU JCAs) began in January 2025. This lesson uses the supplied course blueprint and its named legal framework; it does not provide a complete product-scope or submission-deadline guide.
Prerequisites
None.
Key outputs
You should be able to choose the appropriate decision owner, identify the evidence question and write a conclusion that does not overstate authorisation, comparative benefit, economic value or access.
WHY

Why it matters

  • Evidence can be credible yet insufficient for the decision being requested: a clinical effect estimate does not itself establish economic value.
  • Regulatory authorisation, comparative assessment, reimbursement and price are distinct conclusions. Treating one as proof of another creates avoidable evidence gaps.
  • Since January 2025, EU JCA has added an operating context in which shared clinical assessment must be distinguished from national economic and access decisions.
  • A useful evidence plan names who decides, what they need and which uncertainty remains before selecting analytical methods.
Where things stand: Regulation (EU) 2021/2282 is the framework named in this course for EU JCA. Article 13 addresses the relationship with national HTA. Commission Implementing Regulation (EU) 2024/1381 addresses medicinal-product submission operations. Neither instrument should be treated as evidence that this educational course confers governmental or professional authority.
KEY TERMS

Key Terms & Must-Know Facts

Regulatory benefit-risk evaluation
Evaluation supporting a regulatory decision about a product, with attention to its benefits and risks.
Regulatory authorisation
A product-related permission granted through the relevant regulatory process; it is distinct from payer coverage.
Health technology assessment (HTA)
Assessment of evidence to inform health technology decisions; its specific remit depends on the decision context.
Comparative clinical assessment
Assessment of clinical effects relative to relevant alternatives, including uncertainty and applicability.
Economic evaluation
Comparison of costs and outcomes across alternatives for a specified decision context.
Reimbursement
A funding or coverage determination made through the relevant national or payer arrangements.
Price negotiation
A process concerning price; evidence may inform it, but an effect estimate does not determine its outcome.
EU JCA
Joint clinical assessment addressing relative clinical effects and uncertainty, without determining national economic value, price or reimbursement.
Decision owner
The body or person responsible for the particular decision under consideration.
Evidence analyst
A professional who prepares, appraises, interprets and communicates evidence within the assigned remit.
Applicability
The relevance of evidence to the population, alternatives, outcomes and setting of the decision.
Completion certificate
A record of educational completion, distinct from professional licensure, independent professional certification and regulatory authorisation.
Table 1. Decision questions and defensible outputs
Decision or assessmentPrimary questionDefensible outputInference to avoid
Regulatory evaluationWhat do benefits and risks support within the regulatory remit?A regulatory assessment or authorisation decisionAuthorisation guarantees reimbursement
Comparative clinical assessmentHow do clinical outcomes compare with relevant alternatives?Relative effects, applicability and uncertaintyClinical superiority fixes a price
Economic evaluationHow do costs and outcomes compare in the specified context?Economic results with assumptions and uncertaintyOne result transfers unchanged to every market
ReimbursementWill the relevant arrangement fund or cover the technology?A coverage or funding determinationThe determination is identical to authorisation
Price negotiationWhat price is agreed through the relevant process?A price-related agreement or outcomeA JCA report supplies the negotiated price

Must-know facts:

  • Identify the requested conclusion before assembling evidence.
  • Overlapping evidence does not make decision remits interchangeable.
  • A comparative claim requires attention to the relevant alternative and outcome.
  • EU JCA does not determine national economic value, price or reimbursement.
  • National responsibilities remain relevant after a JCA.
  • Stakeholder contribution and decision authority are different concepts.
  • The course title alone does not establish independent certification or licensure.
CORE

Core content

1.1.1.1 1. Separate the question from the evidence

A Explanation

Decision conflict: A team has a positive clinical result and wants to call the product authorised, clinically preferable, good value and reimbursable. Choose a conclusion matched to the question; reject a chain of unsupported implications.

WHY THIS IS TESTED: In applied work, misclassifying the question sends analysts toward the wrong evidence package. Regulatory evaluation, comparative clinical assessment and economic evaluation can use related studies while requiring different interpretations.

Begin with the verb in the request: authorise, compare, evaluate value, fund or negotiate. Then identify the relevant decision maker. Finally ask whether the evidence addresses that precise conclusion. A regulator may assess comparative information, and an HTA body may use regulatory material; the distinction is the decision remit, not exclusive ownership of particular study designs. See Fig 1.

Fig 1. Route the requested conclusion
Exam takeaway: Classify the decision by its question before selecting evidence.
flowchart TD; A[Requested conclusion] --> B{Primary question}; B --> C[Regulatory benefit and risk]; B --> D[Comparative clinical effects]; B --> E[Costs and outcomes]; B --> F[Coverage or price];
Clinical evidence versus economic evidence
Exam takeaway: A comparative clinical result needs additional contextual inputs before it supports an economic conclusion.
flowchart TD; A[Evidence package] --> B[Clinical comparison]; A --> C[Economic evaluation]; B --> D[Effects and uncertainty]; C --> E[Costs and outcomes in context]; D --> F[Bounded clinical conclusion]; E --> G[Bounded economic conclusion];
Question classification workflow
Exam takeaway: State the intended output before deciding which analysis to perform.
1. Read the requested conclusion.
2. Identify the decision owner.
3. Classify the evidence question.
4. Limit the claim to supported findings.

B Worked example

A developer studies a treatment in adults aged 68 years on average, many with diabetes and chronic kidney disease. A trial reports a better clinical outcome than its comparator. A participant's mildly raised cholesterol appears in the briefing. The commercial slide says, 'Positive trial: reimbursement established.' The most appropriate next step is to correct the decision claim.

  1. Identify the task: Determine what the trial result establishes.
  2. Extract key facts: The supplied information concerns a comparative clinical outcome; no reimbursement determination is described.
  3. Apply the rule: Interpret the clinical result within its population, comparator and uncertainty.
  4. Eliminate: Positive results tempt the team to infer funding, but neither the cholesterol finding nor enthusiasm about the trial supplies a payer decision.
  5. Verify: Replace the slide with a bounded clinical statement and identify the separate reimbursement question.

C Common trap

Wrong answer: Select economic evaluation whenever the word 'benefit' appears. Why tempting: Benefit sounds like value. Single eliminating clue: The request asks only how a clinical outcome compares with an alternative, without a cost question.

D Checkpoint

A brief asks, 'How do symptoms and adverse outcomes compare with current treatment?' Which assessment best matches?

  1. A. Regulatory benefit-risk evaluation
  2. B. Comparative clinical assessment
  3. C. Economic evaluation
  4. D. Reimbursement determination

Answer: B. A is tempting because benefits and harms are mentioned, but the specified task is comparison rather than regulatory permission. B is correct because relative clinical outcomes are the requested output. C is tempting because better outcomes may affect value, but no costs are requested. D is tempting because current treatment may be a funded alternative, but coverage is not the question.

If you missed this: Review Separate the question from the evidence - focus on the requested conclusion rather than shared terminology.

1.1.1.2 2. Map contributions without transferring authority

A Explanation

Decision conflict: The analyst understands the evidence best and is asked to 'approve access.' Choose a clearly assigned analytical contribution; reject an assumption that expertise itself confers decision authority.

WHY THIS IS TESTED: Evidence planning depends on contributions from multiple stakeholders. Responsibility becomes unclear when preparing a recommendation is confused with making the formal decision.

Developers assemble evidence and explain the product evidence package. Regulators act within regulatory processes. HTA bodies assess evidence within their remits. Payers participate in funding and coverage arrangements. Clinicians contribute treatment-pathway and clinical-relevance knowledge, while patients contribute lived experience and outcome priorities. Evidence analysts make methods, sources, assumptions and limitations explicit. These are functional distinctions, not a claim that every jurisdiction uses the same organisational structure.

Table 2. Contributions and authority boundaries
StakeholderRelevant contributionBoundary to preserve
DeveloperPrepare and explain the evidence packageA submission is not the receiving body's decision
RegulatorEvaluate within the regulatory remitAuthorisation is not a payer coverage conclusion
HTA bodyAssess evidence for its decision contextIts exact remit must be identified
PayerAddress funding or coverage within applicable arrangementsDo not assume identical processes across markets
ClinicianExplain pathways, alternatives and clinical relevanceClinical preference alone does not establish economic value
PatientIdentify relevant outcomes, unmet need and lived burdenOne person's experience is not a comparative effect estimate
Evidence analystAppraise and communicate evidence and uncertaintyAnalysis does not itself confer formal decision authority

Use a role map to identify whose input is missing, rather than treating all stakeholders as interchangeable reviewers. See Fig 2.

Fig 2. Contribution is not authority
Exam takeaway: Useful input informs an assessment without automatically transferring the decision right.
flowchart TD; A[Stakeholder input] --> B[Analyst synthesis]; B --> C[Assessment within remit]; C --> D[Responsible decision owner]; B --> E[Documented uncertainty]; E --> C;
Responsibility assignment workflow
Exam takeaway: Name the contributor, deliverable and decision owner separately.
1. Define the deliverable.
2. Identify needed stakeholder input.
3. Assign the analytical owner.
4. Confirm who makes the decision.

B Worked example

An analyst prepares an evidence brief for a population aged 72 years on average with osteoarthritis and hypertension. Patient interviews describe difficulty walking; a clinician highlights treatment-pathway differences. A normal sodium result appears in an appendix. The developer asks the analyst to state that patient enthusiasm 'approves national access.'

  1. Identify the task: Assign appropriate uses of stakeholder input.
  2. Extract key facts: Interviews inform relevant outcomes; clinician input informs pathways; no access decision is documented.
  3. Apply the rule: Integrate these contributions while preserving the responsible body's authority.
  4. Eliminate: Enthusiasm is a tempting access signal, but it is not a formal funding determination. The sodium result does not change the role map.
  5. Verify: Attribute the input, describe its relevance and send the brief through the applicable assessment and decision process.

C Common trap

Wrong answer: Exclude patient input because it does not estimate relative treatment effects. Why tempting: The analyst wants quantitative evidence for every component. Single eliminating clue: The task is to identify meaningful outcomes and unmet need, a distinct contribution from estimating effects.

D Checkpoint

An evidence analyst is asked to sign a statement that a payer has approved coverage, although the analyst has only completed an appraisal. What is the most appropriate response?

  1. A. Sign if the appraisal recommends coverage
  2. B. Ask the developer to countersign the conclusion
  3. C. Report the appraisal and seek confirmation from the responsible decision owner
  4. D. Substitute a clinician's treatment recommendation for the coverage statement

Answer: C. A is tempting because a recommendation may be favorable, but recommendation and determination differ. B is tempting because the developer supplied evidence, but countersignature does not establish payer authority. C is correct because it preserves the appraisal while verifying the decision. D is tempting because clinicians understand treatment need, but a clinical recommendation does not confirm coverage.

If you missed this: Review Map contributions without transferring authority - focus on who owns the formal determination.
Quick Recall:
  • Complete the distinction: preparing an assessment is not the same as making the ______. Answer: decision.
  • Who helps identify lived burden and meaningful outcomes? Answer: Patients, alongside other relevant contributors.
  • True or false: a single study can inform more than one decision question. Answer: True; the interpretation must match each question.

1.1.1.3 3. Carry JCA findings into the national decision context

A Explanation

Decision conflict: A shared clinical assessment is available, and the team wants one Europe-wide value and reimbursement conclusion. Choose reuse of the clinical assessment with explicit national decision needs; reject the assumption that shared assessment settles all downstream decisions.

WHY THIS IS TESTED: EU JCA readiness requires both a clear clinical evidence package and a correct understanding of what national processes still determine.

The supplied blueprint defines JCA as assessment of relative clinical effects and uncertainty. It does not determine national economic value, price or reimbursement. Article 13 of Regulation (EU) 2021/2282 is identified in the blueprint as addressing national due consideration, annexing requirements, non-duplication of evidence requests, complementary national clinical analyses and national added-value conclusions. These features must be understood together: national use of JCA is meaningful, and national assessment responsibilities remain.

For this introductory topic, identify the boundary rather than memorising procedural detail. Exact product eligibility, phased application dates, new-indication provisions, device selection and medicinal dossier deadlines belong to the later JCA operations lessons. The supplied excerpt does not provide all details needed for an individual product determination.

Keep the clinical output and the downstream decision file connected but distinct. See Fig 3.

Fig 3. Shared clinical assessment and national decisions
Exam takeaway: JCA contributes clinical findings while national contexts retain economic, pricing and reimbursement decisions.
flowchart TD; A[EU JCA] --> B[Relative clinical effects and uncertainty]; B --> C[National HTA consideration]; C --> D[Contextual economic assessment]; C --> E[Complementary clinical analyses]; D --> F[National or payer decision process]; E --> F;
Two unsupported shortcuts
Exam takeaway: Avoid both replacing national decisions with JCA and ignoring JCA because those decisions remain national.
flowchart TD; A[JCA available] --> B[Use clinical findings within remit]; A --> C[Shortcut: JCA fixes reimbursement]; A --> D[Shortcut: national process ignores JCA]; B --> E[Map remaining local questions]; C --> F[Reject remit overreach]; D --> G[Reject disregard of national obligations];
JCA handoff workflow
Exam takeaway: Preserve the shared findings and make remaining decision needs explicit.
1. Identify the JCA clinical question.
2. Extract findings and uncertainty.
3. Identify national obligations and needs.
4. Plan complementary work within that remit.
5. Bound the resulting decision claim.

B Worked example

A developer plans national briefs for a treatment studied in adults aged 64 years on average with cancer and cardiovascular disease. A JCA reports comparative clinical effects with uncertainty. A stable haemoglobin value is highlighted in the presentation. A manager proposes, 'Use the same clinical report to announce a single reimbursed price across all markets.'

  1. Identify the task: Translate the shared clinical output into national evidence planning.
  2. Extract key facts: JCA findings are available; national economic and access decisions are not supplied.
  3. Apply the rule: Retain the clinical findings and uncertainty, then identify the relevant national economic, pricing and reimbursement questions.
  4. Eliminate: A single report makes a single decision appear efficient, but JCA does not determine those national outputs. The haemoglobin detail is not the decision discriminator.
  5. Verify: Produce a common clinical evidence summary with a documented list of remaining market-specific questions.

C Common trap

Wrong answer: Treat every national evidence request as permitted because reimbursement remains national. Why tempting: National decision responsibility appears to imply unrestricted re-requesting of evidence. Single eliminating clue: The blueprint explicitly includes non-duplication of evidence requests under Article 13.

D Checkpoint

Which statement most accurately describes the JCA-to-national relationship?

  1. A. JCA establishes relative clinical effects and a uniform national economic value
  2. B. JCA contributes clinical findings and uncertainty while national decision responsibilities remain
  3. C. National reimbursement authority makes consideration of JCA optional in all circumstances
  4. D. National added-value conclusions are excluded whenever JCA exists

Answer: B. A is tempting because shared assessment suggests harmonisation, but national economic value is outside JCA's stated output. B is correct because it combines shared clinical assessment with retained responsibilities. C is tempting because funding remains national, but the blueprint identifies national due consideration. D is tempting because JCA avoids duplication, but the blueprint also recognises national added-value conclusions.

If you missed this: Review Carry JCA findings into the national decision context - focus on the coexistence of shared assessment and national responsibilities.

1.1.1.4 4. Write bounded conclusions and describe your credential accurately

A Explanation

Decision conflict: A polished evidence brief and a course certificate create pressure to claim more authority than either supplies. Choose a precise statement of evidence, uncertainty and educational achievement; reject unsupported decision or credential claims.

WHY THIS IS TESTED: Professional credibility depends on distinguishing what an analysis demonstrates from what a body has decided, and what education documents from what law or an independent certification process authorises.

Use three checks before release: What was assessed? Who owns the decision? What remains unresolved? A conclusion can be useful without claiming final access or value. Separately, describe this course as educational completion. The supplied context does not establish professional licensure, independent professional certification or regulatory authorisation. Its references to EU institutions identify the subject matter and framework; they do not establish that those institutions award this course credential.

Do not invent accreditation, protected-title rights or a certification pathway. If a role requires a particular credential, confirm that requirement through the relevant body rather than inferring it from the course name. See Fig 4.

Fig 4. Validate claims before release
Exam takeaway: Verify both the evidence conclusion and any claim about professional authority.
flowchart TD; A[Draft statement] --> B{Claim type}; B --> C[Evidence or decision]; B --> D[Credential or authority]; C --> E[Check findings and decision owner]; D --> F[Check documented award and rights]; E --> G[Release bounded wording]; F --> G;
Final wording workflow
Exam takeaway: Match each statement to a documented finding, decision or educational record.
1. Identify the proposed claim.
2. Locate its supporting record.
3. Check authority and scope.
4. State limitations and release.

B Worked example

A course graduate prepares a brief for adults aged 59 years on average with rheumatoid arthritis and depression. The report mentions a normal potassium result. An employer proposes the signature line, 'EU-authorised independent HTA certifier,' because the course covers EU regulation.

  1. Identify the task: Determine whether the signature accurately describes the learner's credential.
  2. Extract key facts: Educational completion is documented; independent certification and governmental authorisation are not.
  3. Apply the rule: Describe the completed education without implying additional rights.
  4. Eliminate: The regulatory subject matter makes the proposed title sound plausible, but studying a framework does not confer its authority. Patient characteristics and potassium are irrelevant to credential scope.
  5. Verify: Use wording such as 'Completed the HEOR and Health Technology Assessment Professional Certificate course' and check any separate role requirements.

C Common trap

Wrong answer: Assume that 'Professional Certificate' proves independent certification. Why tempting: The words resemble a professional designation. Single eliminating clue: The blueprint explicitly distinguishes the educational certificate from independent professional certification.

D Checkpoint

Which statement is supported by this course context alone?

  1. A. Completion grants a professional licence to make national HTA decisions
  2. B. Completion establishes independent certification by the EU coordination group
  3. C. Completion documents education without establishing separate professional authority
  4. D. Completion authorises the holder to issue regulatory product approvals

Answer: C. A is tempting because the course develops job-relevant skills, but education is not licensure. B is tempting because EU bodies appear in the subject context, but an awarding or certifying relationship is not established. C is correct because it states the supported educational achievement. D is tempting because regulatory decisions are taught, but learning about authorisation does not grant the power to issue it.

If you missed this: Review Write bounded conclusions and describe your credential accurately - focus on what the completion record actually establishes.
Quick Recall:
  • Does JCA determine national price? Answer: No.
  • Does national responsibility erase JCA-related obligations? Answer: No.
  • Complete the statement: a course completion record establishes ______, not unspecified professional rights. Answer: educational completion.
Regulatory review desk
Exam takeaway: Regulatory review addresses its own benefit-risk question rather than confirming payer coverage.
{"prompt":"Square educational semi-flat illustration on white background: a regulatory reviewer at a desk examining a product evidence folder, with two balanced cards labeled Benefits and Risks and a separate closed folder labeled Coverage. Cool blue and gray, thin outlines, generous margins, no logos, no seals, no implied approval outcome.","caption":"Regulatory review desk","size":"1024x1024"}
Comparative clinical assessment desk
Exam takeaway: Relative effects require an explicit alternative and relevant outcomes.
{"prompt":"Square educational semi-flat illustration on white: evidence analyst compares two equally sized folders labeled Treatment and Alternative, each connected to cards labeled Outcomes and Uncertainty. Include a neutral patient population icon, no numeric results, no price symbols, blue and gray palette, thin lines, generous margins.","caption":"Comparative clinical assessment desk","size":"1024x1024"}
Economic evaluation inputs
Exam takeaway: Economic interpretation connects costs and outcomes within a stated context.
{"prompt":"Square clean educational illustration: two side-by-side treatment folders, each with one cost ledger and one outcomes card, feeding a central worksheet labeled Decision context. Use blue and gray flat vector style on white, no invented monetary values or thresholds, no decorative objects, keep all labels inside broad margins.","caption":"Economic evaluation inputs","size":"1024x1024"}
Stakeholder contribution workshop
Exam takeaway: Patients, clinicians and analysts contribute different information to an evidence plan.
{"prompt":"Square professional educational illustration: patient representative, clinician and evidence analyst seated around a plain table, contributing cards labeled Lived experience, Treatment pathway and Evidence appraisal to a central folder labeled Evidence plan. White background, cool blue and gray, inclusive adult figures, no hospital machinery, no decision approval stamp.","caption":"Stakeholder contribution workshop","size":"1024x1024"}
Shared clinical report and local decision files
Exam takeaway: A common clinical assessment does not supply one universal reimbursement decision.
{"prompt":"Square educational semi-flat illustration: one central report labeled JCA clinical findings above three distinct national decision folders labeled Local context, Economic assessment and Coverage process. Place a small Uncertainty note beside the shared report. White background, blue and gray palette, no country flags, no official EU emblem, no prices or approval stamps.","caption":"Shared clinical report and local decision files","size":"1024x1024"}
Educational completion and professional authority
Exam takeaway: Describe the credential awarded without implying a separate licence or authorisation.
{"prompt":"Square educational comparison illustration on white: left panel shows a plain document labeled Course completion; right panel shows three separate neutral documents labeled Licence, Independent certification and Regulatory authorisation, with a divider and label Separate processes. No seals, signatures, institutional emblems or invented accreditation. Cool blue and gray, generous margins.","caption":"Educational completion and professional authority","size":"1024x1024"}
TRAPS

Exam Traps & Differentiators

Common traps & distractors: The most frequent wrong conclusion is to move from a favorable result directly to a final access claim. It is tempting because all stages concern the same product. The eliminating clue is the absence of a documented decision by the responsible body.
Table 3. Similar wording with different implications
Looks similarDiscriminating clueAppropriate interpretation
Benefit-risk versus comparative clinical effectRegulatory permission versus relative outcomesIdentify the decision remit before classifying the task
Clinical benefit versus economic valueWhether costs and context are assessedDo not substitute an effect estimate for economic evaluation
Recommendation versus reimbursement determinationWhether the responsible body has decidedReport the status actually documented
JCA output versus national added-value conclusionShared clinical assessment versus national interpretationPreserve both the common evidence and the national remit
Certificate versus independent certificationWhat process and award are documentedUse the supported educational description

If the request says...

  • 'May be authorised' → identify the regulatory process and benefit-risk question.
  • 'Compared with current care' → identify relative clinical effects and applicability.
  • 'Costs and outcomes in this setting' → identify the economic evaluation context.
  • 'Will the payer fund it?' → identify the responsible reimbursement arrangement.
  • 'JCA establishes the price' → check for an unsupported extension of the clinical remit.
Open questions and next developments: Product-specific JCA scope, phased implementation and dossier operations require more detail than this introductory source excerpt provides. No proposed future rule is supplied here. In later lessons, distinguish an enacted obligation with an application date from a proposal or planning assumption; use the named authoritative instruments to resolve operational questions.
Review connection: Return to Carry JCA findings into the national decision context when a scenario combines shared evidence with different local conclusions. The next topic, Decision Problem Specification, develops population, alternatives, outcomes, perspective and decision maker into a structured question.
ALGO

Algorithm / Approach

Use this five-step approach when a request bundles clinical, economic and access language into one brief.

Fig 5. Operational decision classification algorithm
Exam takeaway: Separate bundled requests into evidence questions with identifiable owners and bounded outputs.
flowchart TD; A[Identify requested conclusion] --> B[Confirm decision owner and context]; B --> C[Classify clinical economic or access task]; C --> D[Map evidence and unresolved uncertainty]; D --> E[Write supported output and next step];

See Fig 5. A useful handoff records a requested output, responsible owner and evidence gap; it does not simply attach every available study.

1. Identify: Underline the conclusion requested, such as authorisation, comparative effect, value, coverage or price.
2. Confirm: Name the decision owner and relevant context; do not infer them from the sponsor's preferred conclusion.
3. Classify: Split combined requests into separate questions when their evidence requirements differ.
4. Map: Record available findings, applicability limits and unresolved evidence needs.
5. Communicate: State what is supported, what remains undecided and who owns the next action.
QUIZ

Self-check quiz

Select one best answer for each question. The first three items provide a short quick check; complete all five for an integrated review.

1. A product has regulatory authorisation. A stakeholder asks whether its costs and outcomes compare favorably with alternatives in a specified payer setting. What is the most appropriate analytical task?

  1. A. Reinterpret the authorisation as a reimbursement determination
  2. B. Conduct an economic evaluation relevant to that setting
  3. C. Summarise only the regulatory benefit-risk conclusion
  4. D. Treat the comparative clinical effect as the negotiated price

2. A JCA reports relative clinical effects and substantial uncertainty. What is the most appropriate national evidence-planning response?

  1. A. Use the report as a final Europe-wide reimbursement conclusion
  2. B. Disregard the report because reimbursement remains national
  3. C. Use the clinical findings and map remaining national assessment needs
  4. D. Infer a uniform economic value from the shared uncertainty assessment

3. Patient representatives identify fatigue as an important outcome missing from a draft evidence plan. What is the most appropriate interpretation?

  1. A. Their input informs outcome relevance and a potential evidence gap
  2. B. Their input establishes the treatment's relative effect on fatigue
  3. C. Their input establishes that the treatment is cost-effective
  4. D. Their input constitutes a reimbursement recommendation by the payer

4. An analyst writes, 'The trial supports a comparative clinical conclusion; national reimbursement remains to be determined.' A manager asks for a stronger access statement because the treatment is authorised. What is the most appropriate response?

  1. A. Replace the statement because authorisation establishes coverage
  2. B. Retain the bounded statement unless a relevant reimbursement determination is documented
  3. C. Replace the statement if the developer agrees with the clinical result
  4. D. Replace the statement if a clinician prefers the treatment

5. Which credential statement is justified by completion of this course alone?

  1. A. The holder is independently certified by the EU HTA coordination group
  2. B. The holder has a professional licence to issue HTA determinations
  3. C. The holder has completed an educational course in HEOR and HTA
  4. D. The holder is authorised to approve medicinal products
ANSWERS

Answer key & explanations

1. Answer: B. A is tempting because authorisation is an important milestone, but it is not a reimbursement determination. B is correct because the request explicitly combines costs, outcomes, alternatives and a payer setting. C is tempting because the regulatory conclusion is available, but it does not answer the economic question. D is tempting because comparative effects can inform value discussions, but a clinical estimate is not a price agreement.

If you missed this: Review Separate the question from the evidence - focus on costs and outcomes as the discriminator for the economic task.

2. Answer: C. A is tempting because the assessment is shared, but JCA does not determine reimbursement. B is tempting because national responsibility remains, but the blueprint identifies national due consideration and related obligations. C is correct because it uses the shared clinical findings while identifying remaining needs. D is tempting because a common assessment provides a common evidence base, but economic value is not a JCA output.

If you missed this: Review Carry JCA findings into the national decision context - focus on the boundary between shared clinical outputs and national decisions.

3. Answer: A. A is correct because patient input helps identify meaningful outcomes and gaps. B is tempting because lived experience is directly relevant to fatigue, but identifying importance does not estimate relative effects. C is tempting because important outcomes affect value, but costs and comparative outcomes have not been evaluated. D is tempting because patient priorities may inform access discussions, but representatives are not thereby issuing the payer's determination.

If you missed this: Review Map contributions without transferring authority - focus on the specific informational contribution rather than assigning a different decision role.

4. Answer: B. A is tempting because authorisation signals a regulatory decision, but coverage requires its own documented determination. B is correct because the analyst should report the status supported by the record. C is tempting because developer agreement may increase confidence in presentation, but it does not establish payer action. D is tempting because clinical preference is relevant input, but it does not verify reimbursement.

If you missed this: Review Write bounded conclusions and describe your credential accurately - focus on documenting the actual decision rather than inferring it from support.

5. Answer: C. A is tempting because the course discusses EU HTA institutions, but an independent certification award by them is not established. B is tempting because the learning is professionally relevant, but completion is not professional licensure. C is correct because it accurately describes the documented educational achievement. D is tempting because product authorisation is covered in the curriculum, but subject knowledge does not confer regulatory authority.

If you missed this: Review Write bounded conclusions and describe your credential accurately - focus on the difference between education and a separately conferred authority.
RAPID

Rapid review / cheat-sheet

Key points:

  • Question first → classify the requested output before choosing an analytical method.
  • Role map → record contributor, analytical owner and decision owner as separate entries.
  • JCA handoff → carry forward uncertainty alongside clinical findings.
  • Release check → ensure the wording matches the documented assessment or determination.

Retrieval prompts:

  • Mixed request → split it when clinical, economic and funding conclusions require different work.
  • Missing decision record → describe status rather than imply approval.
  • Outcome relevance → use patient input to identify what the evidence plan may overlook.
  • Local adaptation → name the context that makes an additional question necessary.
  • Credential wording → verify the actual award before using a professional designation.
  • Next lesson → turn the decision request into population, alternatives, outcomes, perspective and decision maker.

Blueprint anchor recap: HEOR decisions and evidence planning / Distinguish regulatory, HTA and payer decisions. Coverage includes benefit-risk evaluation, comparative assessment, economic evaluation, reimbursement, price negotiation, stakeholder responsibilities, the EU JCA boundary and educational credential distinctions. Parent domain weight: 10%.

References / further study: The following authoritative instruments are named in the supplied blueprint. This lesson uses the supplied descriptions and does not reproduce unprovided procedural requirements.

  • European Parliament and Council of the European Union. Regulation (EU) 2021/2282 on Health Technology Assessment. 2021. Article 13; articles 7, 9 and 10 provide context for later operational lessons.
  • European Commission. Commission Implementing Regulation (EU) 2024/1381. 2024. Article 12 and Annex I, identified in the course blueprint for medicinal-product dossier operations.
End of your free lesson

Keep going with the full HEOR and Health Technology Assessment Professional Certificate

You just studied the way members do, in the same lesson interface. Full access unlocks every lesson, the question bank and flashcards for a full year.

Up next with full access1.1.2 - Decision Problem Specification

One payment per program